Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Shortened treatment strategy in patients with differentiated thyroid cancer.

- candidate number14669
- NTR NumberNTR3933
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR3-apr-2013
- Secondary IDsNL41880.041.13 / 13-080 CCMO / METC
- Public TitleShortened treatment strategy in patients with differentiated thyroid cancer.
- Scientific TitleFast-track thyroidectomy and radioiodine ablation therapy in patients with differentiated thyroid cancer.
- hypothesisBy reducing the interval between thyroidectomy and radioiodine ablation therapy in patients sick leave time of the patients can be reduced and the quality of life improved. Furhermore costs will for society will be lower.
- Healt Condition(s) or Problem(s) studiedDifferentiated thyroid carcinoma
- Inclusion criteria1. Patients with proven differentiated thyroid cancer, stage T1-3N0-1M0;
2. Planned for total or completion thyroidectomy;
3. Paid job; at least 12 hours per week;
4. Capable of understanding Dutch questionnaires and keeping a diary.
- Exclusion criteria1. Pregnant or breastfeeding patients;
2. T4 (i.e. tumor expansion in vital structures) or M1 tumors;
3. Contrast enhanced CT performed < 4 months prior to inclusion;
4. Hypersensitivity to bovine serum albumin, rhTSH or to any of the excipients;
5. Dialysis-dependent end stage renal disease.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlNot applicable
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-mei-2013
- planned closingdate1-nov-2015
- Target number of participants58
- InterventionsStandard treatment: Thyroidectomy followed by a 4-6 week during waiting period and then ablation with radioactive iodine.

Interventional treatment: Thyroidectomy directly followed by radioactive iodine ablation.
- Primary outcomeDays of sick leave reported from time of surgery.
- Secondary outcome1. Quality of life;
2. Costs associated with productivity at work;
3. Societal costs associated with absence from work.
- TimepointsContinuous monitoring of sick leave and quality of life from start of treatment until 2 months after therapy.
- Trial web
- statusplanned
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
University Medical Center Utrecht (UMCU)
- PublicationsN/A
- Brief summary The initial treatment of patients with differentiated thyroid cancer (DTC) consists of total thyroidectomy followed by thyroid remnant radioiodine ablative therapy (RIT). For successful RIT, elevated levels of thyroid stimulating hormone (TSH) are required. Before the introduction of recombinant human TSH (rhTSH) patients were withheld thyroid hormone substitution therapy for 4 weeks after surgery. Nowadays RIT after rhTSH admission is possible, preventing thyroid hormone withdrawal and subsequent symptoms of hypothyroidism in these patients. Results of RIT after thyroid hormone withdrawal and rhTSH stimulation are comparable. RIT with rhTSH stimulation allows planning of the RIT shortly after thyroidectomy.

We hypothesize that with the availability of rhTSH the treatment of DTC patients in a fast track protocol, i.e. RIT shortly after thyroidectomy, will reduce sick leave time, which will lead to a cost reduction for society, and secondly that the fast track treatment will lead to a higher quality of life for the patients during treatment. Patients will be sooner ‘back on track’. In this way both society and patients will benefit from the implementation of the fast track protocol.
- Main changes (audit trail)
- RECORD3-apr-2013 - 29-sep-2013

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar